Subscribe
9 January 2025NewsCareersMuireann Bolger

Withers & Rogers hires cell and gene therapy expert

Skilled in microbiome, medical devices and next generation diagnostics, the new partner is skilled in creating IP strategies for startups, spinouts and SMEs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Careers
Troutman Pepper Locke exodus sees teams leave in Chicago and London
7 January 2025   Two large teams leave Locke Lord following Troutman Pepper merger | Buchanan opens Chicago office with a large life sciences group | Shoosmiths adds team in London to expand brand-focused IP services.
Careers
Ex-Baker McKenzie patent litigation head joins Morgan Lewis in Germany
7 January 2025   New partner brings technical background in computer science and more than a decade experience in patent litigation | Expertise in tech, engineering, chemical, and life sciences sectors.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle